The discoveries of BRUCE/PTEN dual deficiencies converging on STAT3 hyperactivation and STAT3 inhibition ameliorating MASH reveal mechanistic and therapeutic advance in MASLD/MASH. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.